Achieving “Progress” in Progressive Multiple Sclerosis: Advances in Therapy

Learn about therapies for progressive MS and management of symptoms from faculty expert and a patient with MS.
Daniel Kantor, MD, FAAN
Program Director
person default
Shirley Nedzesky
Format: Microsoft PowerPoint (.ppt)
File Size: 720 KB
Released: November 15, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Sanofi Genzyme

Related Content

Clinical Care Options (CCO) interactive Medical Minute activity of faculty expert and a patient with MS discussing therapies for progressive MS and management of MS symptoms

Daniel Kantor, MD, FAAN
Program Director
person default Shirley Nedzesky
Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Released: November 15, 2021 Expired: November 14, 2022

Listen to one of the world’s leading experts discuss the future of pharmacotherapies for psychiatric disorders. Earn 1 hour of CME/CE credit for free in this online webcast.

Greg Mattingly, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.2 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Physician Assistants: maximum of 1.25 hours of AAPA Category I (Preapproved) credits Released: March 15, 2020 Expired: No longer available for credit

Multiple sclerosis (MS) is a progressive disease of the central nervous system. It affects approximately 1 million people in the US and is most commonly diagnosed between the ages of 20 and 50 years, largely in women. MS causes a variety of motor and nonmotor symptoms and can have devastating effects on productivity and quality of life. This program will review the signs and symptoms of MS to best facilitate early referral for comprehensive neurologic work-up and initiation of disease-modifying therapy (DMT). It will also discuss the primary care clinician’s role in coordinating care, counseling on DMT adherence, and managing the comorbidities of MS.

Mary Knudtson, DNSc, NP, FAAN Claire Riley, MD Released: January 24, 2020

Jiwon Oh, MD, PhD, FRCPC James M. Stankiewicz, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: August 30, 2019 Expired: No longer available for credit

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings